OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Optimising anal cancer screening through risk stratification	337
Lenacapavir: an attractive option, but proceed with caution	165
Risk estimation in HIV reveals our usual blind spots	151
Controversial chronicler of LGBTQ rights	115
A moment of reckoning	112
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	107
Are we ready for long-acting HIV treatment for adolescents?	107
Correction to Lancet HIV 2022; 9: e791–800	105
How do we prevent anal cancer in people living with HIV?	97
The Australian AIDS crisis through the eyes of volunteers	92
HIV and COVID-19: juxtaposition of two pandemics	90
Evidence supports use of on-demand PrEP for HIV prevention	86
Lung cancer in people living with HIV	81
Transplant donation without discrimination	77
Argentina updates HIV laws	75
How much could long-acting PrEP cost in South Africa?	65
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	60
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	60
Steps toward quick and equitable roll-out of lenacapavir	59
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	59
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	57
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	55
All roads lead to Westminster: the infected blood scandal	55
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	55
Redefining care: injectable HIV treatment for adolescents	54

Making America unhealthy again	54
Recent gay Black history in the UK	52
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	52
Sex as a biological variable in HIV-1 and schistosome co-infection	50
Reducing HIV transmission in British Columbia, Canada	50
Dolutegravir in neonates: finally we are getting there!	49
WHO recommends lenacapavir for HIV prevention	48
A public health approach to drug use crucial to ending AIDS	46
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	46
Equitable access to long-acting PrEP on the way?	46
Game-changing study of second-line HIV treatment	45
Unheard testimony	44
Gains and gaps: addressing HIV in diverse sex worker groups	44
Stigma reduction is key to improving the HIV care continuum	43
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	43
Suicide prevention research is crucial to achieving health equity for people with HIV	43
Integration of sexual health and HIV services	43
Fate of people with HIV in jeopardy in Ukraine	43